Wu XL - Search Results

1

Chinese Medicine Treatment on Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Wu XL, Zhuang HF, Zhao YN, Yu XL, Dai TY, Gao RL. Wu XL, et al. Chin J Integr Med. 2020 May;26(5):324-329. doi: 10.1007/s11655-020-3252-y. Epub 2020 Apr 29. Chin J Integr Med. 2020. PMID: 32350801

2

Treatment of Chronic Aplastic Anemia with Chinese Patent Medicine Pai-Neng-Da Capsule () for Replacing Androgen Partially: A Clinical Multi-Center Study.

Jiang ZY, Yu FQ, Gao RL, Kuang YM, Zhu Y, Chen YH, Li LJ, Ouyang GF, Hu J, Wu XL. Jiang ZY, et al. Among authors: wu xl. Chin J Integr Med. 2022 Jan;28(1):20-27. doi: 10.1007/s11655-021-3283-z. Epub 2021 Apr 10. Chin J Integr Med. 2022. PMID: 33837482 Clinical Trial.

3

Chinese Medicine Regulates DNA Methylation to Treat Haematological Malignancies: A New Paradigm of "State-Target Medicine".

Shen FL, Zhao YN, Yu XL, Wang BL, Wu XL, Lan GC, Gao RL. Shen FL, et al. Among authors: wu xl. Chin J Integr Med. 2022 Jun;28(6):560-566. doi: 10.1007/s11655-021-3316-7. Epub 2021 Jul 9. Chin J Integr Med. 2022. PMID: 34241803

4

Comprehensive analysis of the expression and prognosis for TNFAIPs in head and neck cancer.

Lan G, Yu X, Sun X, Li W, Zhao Y, Lan J, Wu X, Gao R. Lan G, et al. Sci Rep. 2021 Aug 3;11(1):15696. doi: 10.1038/s41598-021-95160-x. Sci Rep. 2021. PMID: 34344926 Free PMC article.

5

Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.

Lin M, Wu X, Zhang L, Li L, Wang X, Fu X, Sun Z, Zhang X, Zhu L, Yu H, Chang Y, Nan F, Yan J, Zhou Z, Shi C, Zhang M, Li X. Lin M, et al. Leuk Lymphoma. 2023 Mar;64(3):605-612. doi: 10.1080/10428194.2023.2167492. Epub 2023 Jan 19. Leuk Lymphoma. 2023. PMID: 36657436

6

Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience.

Nan F, Fu X, Chen X, Li L, Li X, Wu J, Feng X, Wu X, Yan J, Zhang M. Nan F, et al. Front Immunol. 2022 Aug 10;13:929221. doi: 10.3389/fimmu.2022.929221. eCollection 2022. Front Immunol. 2022. PMID: 36032118 Free PMC article.

7

Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.

Yu Z, Cai X, Xu Z, He Z, Lai J, Wang W, Zhang J, Kong W, Huang X, Chen Y, Shi Y, Shi X, Zhao Z, Ni M, Lin X, Chen S, Wu X, Chen W, Song Z, Huang C. Yu Z, et al. Oncologist. 2020 Nov;25(11):e1640-e1649. doi: 10.1634/theoncologist.2020-0519. Epub 2020 Jul 25. Oncologist. 2020. PMID: 32533785 Free PMC article. Clinical Trial.

8

Clinical analysis of chronic lung injury in patients with non-Hodgkin lymphoma after CHOP chemotherapy.

Sun Z, Li X, Wu X, Fu X, Li L, Zhang L, Chang Y, Zhang M. Sun Z, et al. Tumour Biol. 2014 Dec;35(12):12601-5. doi: 10.1007/s13277-014-2582-9. Epub 2014 Sep 9. Tumour Biol. 2014. PMID: 25201066

9

Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.

Wu JJ, Wang WH, Dong M, Ma SS, Zhang XD, Zhu LN, Niu ST, Ding MJ, Zhang JM, Zhang L, Li X, Li L, Sun ZC, Wang XH, Fu XR, Li ZM, Chang Y, Nan FF, Yan JQ, Yu H, Wu XL, Zhou ZY, Zhang MZ. Wu JJ, et al. Among authors: wu xl. Invest New Drugs. 2022 Jun;40(3):650-659. doi: 10.1007/s10637-022-01219-5. Epub 2022 Feb 9. Invest New Drugs. 2022. PMID: 35137332

10

B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma.

Wang G, Fu X, Chang Y, Li X, Wu X, Li L, Zhang L, Sun Z, Zhang X, Zhang M. Wang G, et al. Aging (Albany NY). 2019 Jun 13;11(12):3939-3957. doi: 10.18632/aging.102025. Aging (Albany NY). 2019. PMID: 31195368 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,343 results

Search Page